T. Rowe Price and Fidelity Management and Research Company led a $192m Series C round in Cleerly.

T. Rowe Price and Fidelity Management and Research Company led a $192m Series C round in Cleerly, the company creating a new standard of care for heart disease, with participation from Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, and Novartis. "At Cleerly, we are passionate about our mission to create a new standard of care for heart disease. We are grateful for this round of financing that will further enable our work and believe it provides a resounding vote of confidence in our vision for the future of cardiovascular care. The status quo for heart health simply isn’t good enough – for patients, providers, or payors – and our proven approach to examining for early signs of heart disease through the build-up of arterial plaque promises to deliver the change we need right now," James Min, Cleerly CEO and Founder.